The drugmaker acquired the eye division from Nestle in 2010 for $51 billion.
Last October, Novartis CEO Joe Jimenez said it would take longer than expected to turn Alcon’s slow business around, according to the report. The company cites failure to innovate and inconsistent customer service as the source of Alcon’s problems.
“Alcon has not developed over the past two years as we had expected,” said Novartis Chairman Joerg Reinhardt in an interview with the Swiss publication SonntagsZeitung. “In the long run, the question arises as to whether we are the best owner for Alcon.”
More articles on supply chain:
Drug recalls down 20 percent in Q3, device recalls up 29 percent
3 ways Trump may change drug regulation
Medtronic earns FDA approval for ‘smart’ heart defibrillator
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
